Next-generation genome screening is step toward precision cancer medicine for lung cancer

November 14, 2013

Precision cancer medicine has taken a strong step forward at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) with the addition of genome screening for lung cancer.

The technology, known as next generation "multiplex" gene sequencing, analyzes 50-plus genes in DNA extracted from a tumor biopsy for particular genetic mutations. Previous technology required pathologists to analyze one mutation per tissue sample. This second-generation genome sequencing assesses more than 2,500 mutations in a single reaction.

Knowing which mutations are present in lung tumors can help oncologists tailor a patient's treatment to the unique genetic features present in his or her cancer cells. The knowledge can also help in the development of new drugs that target previously unrecognized gene mutations in .

Precision Cancer Medicine Driven By DNA

Information from these tests is now critical for determining the most effect therapies, says medical oncologist David Carbone, MD, director of the OSUCCC – James Thoracic Oncology Program. "Tumors that bear certain often respond better to drugs designed to target those mutations than to standard chemotherapy."

The video will load shortly

"Each patient's cancer is genetically distinct, so we must customize our treatments as well," says Greg Otterson, MD, co-director of the OSUCCC – James Thoracic Oncology Program. "Genomic testing of tumor cells in many cases helps us match a specific patient with the therapy or clinical trial most likely to have a positive effect on his or her cancer."

"For example, a patient could be given a standard chemotherapy and expect a 35 percent response rate/shrinkage of tumor. But if we know that patient has a mutation in a gene called EGFR, we can offer him a pill (erlotinib), which has a 75 percent response rate—and fewer side effects," he adds.

Gene sequencing is now considered the standard of care for stage-4 patients at The OSUCCC – James and a handful of other centers across the United States. Several clinical trials evaluating molecular targeted therapies for patients with stage-3 lung cancers will soon at The OSUCCC – James.

"In addition to doing a far better job of finding , this technology is faster, uses patients' tumor samples efficiently and reduces the cost of genomic testing, making it accessible to more patients," adds Weiqiang Zhao, MD, PhD, assistant professor of pathology and a member of the OSUCCC – James Molecular Biology and Cancer Genetics Program. Zhao directs the molecular pathology laboratory at The Ohio State University Wexner Medical Center where clinical genome sequencing is performed and analyzed. The lab is accredited by Clinical Laboratory Improvement Amendments (CLIA) for quality.

Lung cancer is the No. 1 cause of cancer death in the United States and the world among both men and women. More than 200,000 cases are diagnosed annually in the United States, and approximately 50 percent of these have metastatic disease at diagnosis, which is generally considered incurable. Although the majority of people with lung have a history of smoking, 15-20 percent of people affected by the disease in the United States have never smoked, and another 40-45 percent have successfully quit smoking.

Explore further: MicroRNA molecule found to be a potent tumor-suppressor in lung cancer

Related Stories

MicroRNA molecule found to be a potent tumor-suppressor in lung cancer

September 16, 2013
New research shows that microRNA-486 is a potent tumor-suppressor molecule in lung cancer, and that the it helps regulate the proliferation and migration of lung-cancer cells, and the induction of programmed cell death, or ...

Study finds new genetic error in some lung cancers

October 28, 2013
A fine-grained scan of DNA in lung cancer cells has revealed a gene fusion – a forced merger of two normally separate genes – that spurs the cells to divide rapidly, scientists at Dana-Farber Cancer Institute and the ...

HPV can damage genes and chromosomes directly, whole-genome sequencing study shows

November 7, 2013
The virus that causes cervical, head and neck, anal and other cancers can damage chromosomes and genes where it inserts its DNA into human DNA, according to a new study led by researchers at The Ohio State University Comprehensive ...

Tumors with ALK rearrangements can harbor more mutations

April 22, 2013
The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment. Although the mutations driving many lung carcinomas remain unknown, approximately 50 percent of lung ...

Testing for mutations identified in squamous cell lung cancer tumors helps personalize treatment

May 17, 2012
Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations ...

Major cancer genotyping study logs 5,000th tumor profile

September 12, 2013
More than 5,000 genetic profiles of tumor DNA have been completed in a large research study by scientists at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Boston Children's Hospital designed to speed the ...

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.